The opinion in support of the decision being entered
today was not written for publication and is not
binding precedent of the Board.
Paper No. 60
Filed by: Merits Panel
Box Interference
Washington, D.C. 20231
Tel: 571-272-9797
Fax: 571-272-0042
UNITED STATES PATENTAND TRADEMARK OFFICE MAILED
I DEC 2 9 2004
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES PAT &T.M OFFICE
BOARD 6F PATENT APPEALS
L AND INTERFERENCES
FALKO-GUNTER FALKNER, GEORG HOLZER AND FRIEDRICH DORNER URQHART
Junior.Partyl
V.
STEPHEN C. INGLIS, MICHAEL E.G. BOURSNELL, ANTHONY C. MINSON
Senior Part Y2
Application 08/802,985, filed February 21, 1997, now U.S.
Patent Number 5,770,212, issued on June 23, 1998. Said
patent accorded benefit of: U.S. Application Serial
Number 08/616,133, filed 'December 22, 1999, and now U.S.
Patent Number 5,766,882, issued on June 16, 1998; U.S.
Application Serial Number,08/235,392, filed on April 24,
1994, and now abandoned. Assigned to Immuno
Aktiengesellschaft, Austria. Hereinafter, the junior
party is referred to as "Falkner."
1
Application Serial Number 08/459,040, filed June 2,
1995. Accorded benefit of: U.S. Application Serial
Number 08/384,963, filed February 7, 1995, now U.S.
Patent Number 5,665,362, issued September 9, 1997; U.S.
Application Serial Number 08/030,373, filed May 20,
1993, and now abandoned; PCT/GB91/01632, filed September
23, 1991, published as WO 92/05263; GB 9104903.1, filed
March 8, 1991; and GB 9020799.4, filed September 25,
1990. Assigned to Cantab Pharmaceuticals Research
Limited, UK. Hereinafterthe senior party is referred to
as "Inglis."
Page: 1 2 3 4 Next
Last modified: November 3, 2007